ten23 health

What ten23 health does

ten23 health is a Swiss contract development and manufacturing organization (CDMO) that develops and manufactures sterile injectable drug products for pharmaceutical companies and biotech startups. Founded in 2021 and headquartered in Basel, Switzerland, the company operates through three integrated service pillars: Pharmaceutical Product Development (formulation, analytical and process development, drug-device integration), Drug Product Manufacturing (clinical and commercial fill-finish of vials, syringes, and cartridges), and Analytical Testing & Quality Control (cGMP release and stability testing). Its core technology platform is built around state-of-the-art isolator technology for aseptic manufacturing, with specialized capabilities including ultra-precise small-volume filling (100 µL bubble-free), lyophilization (2x 12.5 m² capacity), high-viscosity formulation filling, and combination product development with wearable injectors, autoinjectors, and prefilled syringes via partnerships with BD, West, SHL Medical, and Ypsomed.

The company operates from three facilities: BASE® in Basel (development, non-GMP sterile manufacturing, QC testing), VIVA1® in Visp (GMP fill-finish Line 1), and VIVA2® in Visp (Lines 2 and 3, opened 2024, including FDA-approved QC labs and ATMP manufacturing licenses). ten23 is the first B Corp-certified sterile drug product CDMO in the pharmaceutical sector and holds FDA QC lab approval, Swissmedic GMP, ATMP GMP, and ISO 9001:2015 certifications. It is privately held and backed by 3i Group since its founding, with a 2024-2025 expansion of leadership team (CBO, COO, C-People) and 2026 APAC expansion via a Tokyo office.

ten23's revenue model is project-based B2B CDMO services, with quoted contracts (not publicly disclosed pricing) spanning clinical and commercial supply. The company reaches customers through direct enterprise sales, regional business development directors, and active participation in industry conferences (CPHI, PDA, BIO-Europe). Customer segments include large pharmaceutical companies requiring injectable biologic CDMO support and biotech startups needing integrated end-to-end services from early development through commercial supply. Notable commercial successes include supporting scPharmaceuticals' FDA-approved FUROSCIX (first FDA-approved subcutaneous loop diuretic).

Name

ten23 health

Legal name

ten23 health AG

Website

https://ten23.health

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

ten23 health is a Swiss CDMO that develops and manufactures sterile injectable drug products for pharmaceutical companies and biotech startups, offering integrated formulation development, aseptic fill-finish manufacturing, and cGMP quality control testing from facilities in Basel and Visp.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Sterile injectable manufacturing
• Pharmaceutical CDMO services
• Aseptic fill-finish
• Biologics drug development
• Sterile drug products

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. CDMO Services: Contract development and manufacturing services for sterile drug products including formulation development, analytical testing, process development, and fill-finish manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech clients for both clinical and commercial supply.
2. GMP Manufacturing: Clinical and commercial sterile fill-finish manufacturing services including vials, syringes, cartridges, and drug-device combination products
3. QC/Analytical Testing Services: Quality control release and stability testing services for clinical and commercial sterile drug products under cGMP conditions

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

ten23 health is a Swiss CDMO that provides formulation development, analytical and process development, sterile aseptic fill-finish manufacturing, and cGMP quality control testing for injectable drug products. The company serves pharmaceutical companies and biotech start-ups with both clinical and commercial supply capabilities across vials, syringes, cartridges, and drug-device combination products. Its services span small-molecule and biologic modalities, including monoclonal antibodies, peptides, oligonucleotides, and advanced therapy medicinal products (ATMPs), delivered from facilities in Basel and Visp, Switzerland.

Product overview

ten23 health is a human-centric and sustainable CDMO (Contract Development and Manufacturing Organization) offering integrated pharmaceutical services for the formulation, analytical and process development, sterile manufacturing (fill&finish), and testing of injectable medicines. The company operates through three interconnected service pillars: Pharmaceutical Product Development (formulation, analytical development, drug/device integration), Drug Product Manufacturing (clinical and commercial fill & finish via VIVA1® and VIVA2® facilities in Visp), and Analytical Testing & Quality Control (cGMP release and stability testing via BASE® and VIVA2® facilities). The portfolio spans from early-stage development through commercial supply, supporting diverse therapeutic modalities including monoclonal antibodies, peptides, oligonucleotides, and advanced therapies, with specialized capabilities in drug-device combination products through partnerships with device manufacturers.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Product Development
• Drug Product Manufacturing (Fill & Finish)
• Analytical Testing & Quality Control
• BASE® (Basel Development Facility)
• VIVA1® (Visp Manufacturing Line 1)
• VIVA2® (Visp Manufacturing Lines 2 & 3)
• Drug/Device Combination Products
• Line 0 (Pilot Line)

Quantifiable outcome

• First and only FDA-approved subcutaneous loop diuretic (FUROSCIX) supported by ten23 for scPharmaceuticals
• +1 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature7 records

Partnerships

13 partnerships are on record, tiered minor and core.

• dsm-firmenichminorStrategic or Co-development Partner · 15 July 2026Research collaboration focused on expanding excipient options for parenteral biologic drug products.
• West Pharma (SmartDose S1)minorStrategic or Co-development Partner · 4 May 2026Successfully tested and ran the newly launched West Synchrony™ S1 prefillable syringe (PFS) system on ten23's manufacturing equipment to ensure manufacturing readiness.
• BD (Becton, Dickinson and Company)coreStrategic or Co-development Partner · 20 January 2026Manufacturing collaboration to support commercialization of the BD Libertas™ wearable injector for subcutaneous drug delivery. Partnership combines BD's wearable on-body injector platform with ten23's process development, aseptic filling, assembly, and quality control services for fully integrated, ready-to-use solution for large-volume injectable programs.
• Neumirna TherapeuticsminorStrategic or Co-development Partner · 27 October 2025Partnership to develop RNA therapy (NMT.001) for drug-resistant epilepsy, aiming to accelerate clinical translation of microRNA-targeting therapy.
• YpsomedcoreStrategic or Co-development Partner · 16 April 2024Collaboration for commercialization of the YpsoDose wearable injector for subcutaneous self-injection of large-volume doses. ten23's drug development, filling and device assembly expertise contributes to the integrated product offering.
• SHL MedicalcoreStrategic or Co-development Partner · 25 March 2024Strategic partnership to provide streamlined offering for pharmaceutical and biotech companies requiring sterile drug/device combination products. SHL Medical provides patient-centric solutions for design, development, and manufacturing of autoinjectors, pen injectors, and specialty delivery systems.
• West PharmacoreStrategic or Co-development PartnerPartnership to deliver integrated solution with filled Daikyo Crystal Zenith® cartridges for the SmartDose wearable injector, accelerating clinical development and enabling customers to bring innovative injectable drugs to market. Partnership originally initiated with sister company swissfillon.
• Alliance for RTUminorOthersten23 health joined the Alliance for RTU, an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing. Provides expert platform to share expertise and technical knowledge on high-quality ready-to-fill sterile primary packaging.
• ClimeworksminorOthersClimeworks provides carbon dioxide removal as a service via direct air capture and storage (DAC+S) technology. Supports ten23's vision for carbon neutrality.
• FurthrminorOthersClimate app helping individuals take holistic climate action with combined focus on climate literacy, emission reduction, carbon offsetting and personal advocacy. Colleagues at ten23 use the Furthr app for individual climate action.
• Leaders For Climate Action (LFCA)minorOthersEurope's biggest climate action community accelerating progress towards Paris Agreement goals through bold leadership and open collaboration.
• Seven Clean SeasminorOthersOcean Clean-up Organisation based in Singapore removing plastic from oceans and beaches, supporting ten23's environmental initiatives.
• The Generation ForestminorOthersCooperative planting forests in Panama to counter deforestation and extract CO2 from atmosphere naturally, supporting ten23's sustainability goals.

Scale indicators5 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Vetter Pharma: Germany-based CDMO specializing in aseptic fill-finish and lyophilization for injectable drugs, including drug-device combination products. Closely comparable to ten23 in focus on sterile injectables and complex biologics, with a more mature operational history.
• Recipharm: European CDMO offering sterile fill-finish and pharmaceutical development services. Comparable to ten23 in target customers (pharma and biotech) and service mix spanning formulation, manufacturing, and analytical testing.
• Aenova: Sterile injectable CDMO with capabilities in fill-finish, lyophilization, and combination products. Comparable European-headquartered CDMO focused on parenteral manufacturing and serving similar biotech and pharma clients.
• Siegfried Holding: Swiss-based CDMO with sterile drug product manufacturing services. Andrea Wesp's recent tenure at Siegfried underscores operational overlap with ten23 in sterile fill-finish and parenteral drug product manufacturing.
• WuXi STA (WuXi AppTec): Chinese-headquartered CDMO with large-scale sterile injectable and biologics manufacturing. Overlaps with ten23's parenteral CDMO offering, particularly for biologics and complex modalities, though with a different geographic and operational footprint.
• Bora Pharmaceuticals: CDMO offering sterile injectable fill-finish and pharmaceutical development services. Comparable customer base and CDMO service model, with overlap in parenteral drug product manufacturing.

Broad incumbents

• Lonza Group: One of the largest global CDMOs with extensive sterile fill-finish capacity and biologics manufacturing services. Overlaps with ten23's core parenteral CDMO offering, though operating at a much larger scale across multiple modalities.
• Catalent: Large global CDMO with significant sterile injectable fill-finish capacity. Comparable service offerings across biologics and parenteral manufacturing, though at substantially greater scale and broader geographic reach.
• Thermo Fisher Scientific (CDMO): Through its CDMO services, offers sterile injectable manufacturing and related pharmaceutical development services. Comparable business model at significantly larger scale, including the clinical trial services segment where ten23's CFO previously worked.

Others

• West Pharmaceutical Services: Primary packaging and delivery device manufacturer for injectable drugs. Listed as a partner of ten23 (SmartDose, Daikyo Crystal Zenith cartridges, Synchrony S1) but operates as an adjacent industry participant enabling combination products rather than a direct CDMO competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ten23 health